New drug MR13A9 shows promise for Dialysis-Related itching
NCT ID NCT03802617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tested a drug called MR13A9 in 247 Japanese adults on hemodialysis who had severe itching (uremic pruritus). Participants received either MR13A9 or a placebo intravenously. The goal was to see if the drug reduces itch intensity over 8 weeks. Results could lead to a new treatment for this uncomfortable condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MR13A9 (a drug given intravenously)
- What this could lead to
- If successful, this could provide a new treatment option for severe itching in people on dialysis.
- What could go wrong
- This is a Phase 2 trial, so it is still early. The drug may not prove effective or safe enough for approval. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.